CTRI/2024/04/066435Not yet recruitingPhase 4
A Study of the Efficacy and Safety of Combination of Omega-3 Fatty Acids and Vitamin E versus Combined Oral Contraceptive Pills in Polycystic Ovarian Syndrome - NI
Pandit B. D. Sharma UHS Rohtak0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Females of age group (15-45 years).
- •2.Subjects diagnosed with PCOS according to modified 2018 criteria (Rotterdam criteria): Presence of 2 out of 3 traits.
- •a.v Presence of Hyperandrogenism (clinical and/or biochemical)
- •b.v Oligo/Anovulation
- •c.v PCOM (Polycystic ovarian morphology)- at least one ovary with
- •i=20 follicles per ovary in either ovary
- •ii=10 cm3 of ovarian volume
- •3.Patients willing to give written informed consent/assent.
Exclusion Criteria
- •1.Any history of Neoplastic disease.
- •2.Endocrinal disorders like Hyperprolactinemia, Hyper/ Hypo Thyroidism and Acromegaly.
- •3.Functional Hypothalamic amenorrhoea.
- •4.Already on PCOS treatment or have taken Vitamin supplements in the last 3 months.
- •5.Females who are either pregnant, willing to become pregnant or lactating.
- •6.Any Chronic Liver or renal disease.
Investigators
Similar Trials
Completed
Not Applicable
Investigation on efficacy and safety of combination treatment with imidafenacin and mirabegron in patients with overactive bladder.overactive bladderJPRN-UMIN000016236Clinical Research Support Center Kyushu30
Completed
Phase 2
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcomasoft tissue cancer10072990NL-OMON39691Morphotek, Inc10
Active, not recruiting
Phase 1
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.EUCTR2012-001399-12-NLMorphotek Inc.200
Active, not recruiting
Phase 1
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.Metastatic Soft Tissue SarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001399-12-BEMorphotek Inc.200
Completed
Not Applicable
Effect of the combination of artificial dura and umbilical cord and placenta mesenchymal stem cell-derived exosomes in patients with complete spinal cord injuryComplete spinal cord injury.Injury of spinal cord, level unspecifiedT09.3IRCT20200502047277N1Shahid Beheshti University of Medical Sciences60
